Ironwood Pharmaceuticals Stock News

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Director Julie Mchugh sold 10,000 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Tuesday, December 14th. The shares were sold at an average price of $11.02, for a total transaction of $110,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is []

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Director Julie Mchugh sold 10,000 shares of the companys stock in a transaction that occurred on Tuesday, December 14th. The shares were sold at an average price of $11.02, for a total value of $110,200.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the []

TheStreet lowered shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from a b- rating to a c rating in a research report report published on Wednesday morning, TheStreetRatingsTable reports. A number of other research firms have also recently commented on IRWD. Morgan Stanley upped their price target on shares of Ironwood Pharmaceuticals from $13.00 to $14.00 and gave [] The post Ironwood Pharmaceuticals (NASDAQ:IRWD) Rating Lowered to C at TheStreet appeared first on ETF Daily News .

Wall Street analysts expect that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will post earnings of $0.31 per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Ironwood Pharmaceuticals earnings, with the highest EPS estimate coming in at $0.36 and the lowest estimate coming in at $0.28. Ironwood Pharmaceuticals posted []

Equities analysts forecast that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will announce earnings of $0.31 per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Ironwood Pharmaceuticals earnings, with estimates ranging from $0.28 to $0.36. Ironwood Pharmaceuticals reported earnings of $0.36 per share in the same quarter last year, which []

Hillsdale Investment Management Inc. lifted its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 12.6% in the third quarter, HoldingsChannel.com reports. The firm owned 340,617 shares of the biotechnology companys stock after purchasing an additional 38,000 shares during the quarter. Hillsdale Investment Management Inc.s holdings in Ironwood Pharmaceuticals were worth $4,449,000 at the end of the []

The world class Irritable Bowel Syndrome (IBS) Market report studies extensive evaluation of the market growth predictions and restrictions. The strategies range from new product launches, expansions, agreements, joint ventures, partnerships, to acquisitions. This report comprises of a deep knowledge

Foundry Partners LLC acquired a new position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 893,070 shares of the biotechnology companys stock, valued at approximately $11,663,000. Foundry Partners LLC owned approximately 0.55% of Ironwood Pharmaceuticals []

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) COO Jason Rickard sold 17,193 shares of the companys stock in a transaction on Tuesday, November 23rd. The shares were sold at an average price of $11.58, for a total value of $199,094.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through []

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CEO Thomas A. Mccourt sold 52,644 shares of the stock in a transaction dated Tuesday, November 23rd. The stock was sold at an average price of $11.58, for a total transaction of $609,617.52. The sale was disclosed in a document filed with the SEC, which is available at this link. Shares []

Related Stocks: IRWD ,

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) COO Jason Rickard sold 17,193 shares of the firm’s stock in a transaction that occurred on Tuesday, November 23rd. The stock was sold at an average price of $11.58, for a total transaction of $199,094.94. The sale was disclosed in a document filed with the SEC, which can be accessed through […]

Price T Rowe Associates Inc. MD decreased its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 12.0% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 132,845 shares of the biotechnology companys stock after selling 18,069 shares during the quarter. Price T Rowe Associates Inc. MDs holdings in Ironwood Pharmaceuticals were worth $1,710,000 as []

Wall Street brokerages expect Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to report sales of $109.58 million for the current quarter, according to Zacks. Two analysts have provided estimates for Ironwood Pharmaceuticals earnings, with the highest sales estimate coming in at $110.16 million and the lowest estimate coming in at $109.00 million. Ironwood Pharmaceuticals reported sales of $116.68 []

Marshall Wace LLP grew its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 3,037.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 418,870 shares of the biotechnology companys stock after acquiring an additional 405,520 shares during the quarter. Marshall Wace LLPs holdings in Ironwood []